News | May 23, 2012

Accumetrics Sees Significantly Increased Interest in VerifyNow P2Y12 Test as Plavix Loses Patent Protection

Platelet Reactivity Testing Can Benefit Patients, Providers and Payers

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that the introduction of multiple, new generic versions of clopidogrel into the U.S. market has led to increased interest in platelet reactivity testing. In addition to increased field interest, Accumetrics reports a 40 percent jump in traffic to its VerifyNow website.

While the less expensive, generic versions of clopidogrel provide a cost benefit to patients and insurers, it has been well-established that approximately one-third of patients do not respond adequately to clopidogrel.

"Inadequate response to clopidogrel is associated with a significantly increased rate of adverse events, such as heart attack and stent thrombosis, which can lead to 30-day rehospitalization,” said Matthew J. Price, M.D., of the Scripps Translational Science Institute and Scripps Clinic in La Jolla, Calif. “For the best overall healthcare quality and cost metrics, getting the right patient on the right drug is critical. Rapid, point-of-care platelet reactivity testing helps us determine the most appropriate antiplatelet treatment option."

Payers can also benefit from integrating platelet reactivity testing into managed care. In fact, several health plans across the nation have already created prior authorization requirements for the more potent branded drugs, Effient and Brilinta, with clopidogrel non-responsiveness as justification for prescribing them.

“Due to the increased cost of newer, more potent P2Y12 inhibitors, we often have third-party payers in this area decline payment unless it has been proven that the patient does not respond to clopidogrel,” said Paul Huang, M.D., interventional cardiologist at Seattle’s Swedish Heart and Vascular Institute. “The VerifyNow P2Y12 Test results have satisfied the payers in this area.”

John Mackowiak, Ph.D., of the Center for Outcomes Research, Nashville, Tenn., has developed a pharmacoeconomic model analyzing the budget impact of antiplatelet therapy management alternatives. “A health plan that adds platelet reactivity testing for stent patients on antiplatelet therapy could save 3-5 percent of their costs annually through reduced drug and rehospitalization expense,” said Mackowiak.

The VerifyNow System is currently used clinically by physicians in more than 800 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

"The VerifyNow System’s PRU results have become a standard tool to help healthcare professionals determine the most cost-effective and clinically appropriate solutions for patients on antiplatelet medications," said Timothy I. Still, president and CEO of Accumetrics. “Accumetrics foresees continued strong demand worldwide for our portfolio of VerifyNow platelet reactivity tests.”

For more information: www.accumetrics.com.

Related Content

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Overlay Init